in silico trials have become a concrete and important option to predict drug efficacy and optimize time and costs of clinical development.
Novadiscovery is a French health-tech company, which performs in silico trials for pharma and biotech companies with the aim of reducing research & development (R&D) costs and time-to-market of novel drugs.
At the beginning of the new year, they officially announced to have closed the first 5 million euros of a 7 million euros Series A funding round with Debiopharm. Novadiscovery will use the funding to scale its in silico clinical trial simulation platform, enabling its clients to directly conduct their in silico trials, and to develop its presence on the US market, the largest market globally for drug development.
This is a really important sign of the increased maturity level of in silico clinical trials!
Full information can be found on the official press release